补骨脂素加紫外线A、依曲替酯以及补骨脂素加紫外线A与依曲替酯联合治疗掌跖脓疱病。一项安慰剂对照比较试验。

PUVA, etretinate, and PUVA-etretinate therapy for pustulosis palmoplantaris. A placebo-controlled comparative trial.

作者信息

Rosén K, Mobacken H, Swanbeck G

出版信息

Arch Dermatol. 1987 Jul;123(7):885-9. doi: 10.1001/archderm.1987.01660310053013.

DOI:10.1001/archderm.1987.01660310053013

Abstract

Thirty patients with severe pustulosis palmoplantaris completed a placebo-controlled comparative trial. Patients were randomly allocated to placebo or etretinate therapy; after two weeks, psoralen plus long-wave ultraviolet light (PUVA) treatment was instituted on one hand or foot, while the other hand or foot served as an untreated control. Fourteen of 18 hands or feet cleared with the combined treatment, compared with three of 18 with etretinate treatment and three of 12 with PUVA treatment. Follow-up showed a high relapse rate. Treatment of severe pustulosis palmoplantaris must be individualized to minimize short- and long-term side effects.

摘要

30例重度掌跖脓疱病患者完成了一项安慰剂对照的比较试验。患者被随机分配接受安慰剂或依曲替酯治疗；两周后，对一只手或脚进行补骨脂素加长波紫外线（PUVA）治疗，而另一只手或脚作为未治疗对照。联合治疗的18只手或脚中有14只病情好转，依曲替酯治疗的18只中有3只好转，PUVA治疗的12只中有3只好转。随访显示复发率很高。重度掌跖脓疱病的治疗必须个体化，以尽量减少短期和长期副作用。